Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its earnings data on Thursday. The company reported ($0.19) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.17) by $0.02,American Banking News.com reports. The company had revenue of $12.50 million for the quarter, compared to the consensus estimate of $21.80 million. During the same quarter in the prior year, the company posted ($0.04) earnings per share. The company’s quarterly revenue was down 42.7% on a year-over-year basis. Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock opened at $15.40 in last session, and closed at $14.09, while the day range of HALO stock is $13.50-$15.57.The stock showed a negative weekly performance of -9.97%.
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) announced its 2013 financial results and reviewed the highlights of the year. Isis ended the year in a strong financial position and outperformed both its pro forma net operating loss (NOL) guidance and its cash guidance for the year. For the year ended December 31, 2013, Isis had an NOL of $40.2 million compared to $60.4 million for 2012. Isis’ strong financial performance in 2013 is the result of the Company’s successful execution of its business strategy. Isis added a substantial amount of cash to its balance sheet in 2013, ending the year with $657 million. The increase in the Company’s cash position was primarily due to the significant amount of cash received from its partners as well as the net proceeds from the equity offering it completed in 2013. On a GAAP basis, Isis reported a loss from operations of $19.9 million and $51.7 million for the three and twelve months ended December 31, 2013, respectively, compared to $26.1 million and $68.9 million for the same periods in 2012. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) stock opened at $57.03, in last session and closed at $51.00, by loosed -9.53%.The 52 week range was $14.50-$62.66.Company’s market capitalization is $5.92 billion.
In a 13G filing on Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), hedge fund Integrated Core Strategies (US) LLC disclosed a 4.4%, or 3,207,605 share, stake in the company. This is down 1.58% from the 3,259,133 shares held at the end of the latest quarter ending September 30, 2013. Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) stock loosed -6.67% and finished the last session at $5.79.The EPS of the stock remained -0.64.Company’s market capitalization is $368.77 million.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) is a leading oncology name to buy at Jefferies. The company is primarily focusing on developing its lead cancer drug ganetespib as a treatment for non-small-cell lung cancer, breast cancer and colorectal cancer. If approved, the drug is expected to hit annual peak sales of $425 million to $600 million. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) stock opened the session at $6.63, and closed the session at $6.18.The 52 week range of the SNTA stock remained $3.70-$10.74 and the day range was $6.07-$6.64.